scispace - formally typeset
Y

Yuko Kawano

Researcher at Kobe University

Publications -  31
Citations -  495

Yuko Kawano is an academic researcher from Kobe University. The author has contributed to research in topics: Bone marrow & Haematopoiesis. The author has an hindex of 8, co-authored 21 publications receiving 383 citations.

Papers
More filters
Journal ArticleDOI

Matrix-Embedded Osteocytes Regulate Mobilization of Hematopoietic Stem/Progenitor Cells

TL;DR: It is demonstrated that osteocytes, the major cellular component of mature bone, are regulators of HSPC egress and the BM/bone niche interface is critically controlled from inside of the bone matrix and establish an important physiological role for skeletal tissues in hematopoietic function.
Journal ArticleDOI

Osteocytes Regulate Primary Lymphoid Organs and Fat Metabolism

TL;DR: A role for osteocytes as critical regulators of lymphopoiesis and fat metabolism is defined and it is suggested that bone acts as a central regulator of multiple organs.
Journal ArticleDOI

G-CSF-induced sympathetic tone provokes fever and primes antimobilizing functions of neutrophils via PGE2

TL;DR: A novel mechanistic insight is provided into the communication of the nervous system, BM niche components, and hematopoietic cells and sympathetic denervation eliminated both neutrophil priming for PGE2 production and fever during G-CSF treatment, identifying sympathetic tone-primed BM neutrophils as one of the major PGE 2 producers.
Journal ArticleDOI

Posttranscriptional modulation of cytokine production in T cells for the regulation of excessive inflammation by TFL.

TL;DR: TFL is a novel gradual and persistent posttranscriptional regulator, and the TFL-driven attenuation of excessive inflammation could contribute to recovery from T cell–mediated autoimmune diseases.
Journal ArticleDOI

Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation

TL;DR: MMF administration of every 8 h after alloSCT would be better to maintain higher MPA plasma levels than that of every 12 h even in the same daily dose, according to real-time pharmacokinetic monitoring.